Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

If approved, Beyfortus would become the first ... of protecting all infants against RSV with a single dose." Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing ...

"Parents and caregivers across Ontario have the opportunity to protect infants and all newborns from RSV with Beyfortus® (nirsevimab). Sanofi is proud to partner with the Government of Ontario to ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

TORONTO, Oct. 28, 2024 /CNW/ - Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...

Sanofi is listed on (EURONEXT: SAN) and (NASDAQ: SNY) i BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, ...

With almost EUR3 billion in the first nine months, our launches have become significant contributors to Sanofi's accelerated ...

Beyfortus Sales Projection: Expected to reach around ... Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales ...

Sanofi SNY reported third-quarter 2024 adjusted earnings of ... driven by earlier-than-anticipated deliveries of respiratory syncytial virus (RSV), vaccine Beyfortus and flu vaccines. In Immunology, ...